Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)

Belantamab mafodotin (belamaf) demonstrated deep and durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM) in DREAMM-2 (NCT03525678). Corneal events, specifically keratopathy (including superficial punctate keratopathy and/or microcyst-like epithelial c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Cancer J
Main Authors: Lonial, Sagar, Nooka, Ajay K., Thulasi, Praneetha, Badros, Ashraf Z., Jeng, Bennie H., Callander, Natalie S., Potter, Heather A., Sborov, Douglas, Zaugg, Brian E., Popat, Rakesh, Degli Esposti, Simona, Byrne, Julie, Opalinska, Joanna, Baron, January, Piontek, Trisha, Gupta, Ira, Dana, Reza, Farooq, Asim V., Colby, Kathryn, Jakubowiak, Andrzej
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8155129/
https://ncbi.nlm.nih.gov/pubmed/34039952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-021-00494-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados